Press Releases

We lead the synthetic biology industry, having developed and successfully commercialized the most Lab-to-Market™ ingredients. Our sustainable ingredients are used in thousands of top global brands, including our own family of consumer brands in Clean Beauty and Health markets.

Amyris Reports Third Quarter 2012 Financial Results

EMERYVILLE, Calif.Nov. 6, 2012 (GLOBE NEWSWIRE) -- Amyris, Inc. (Nasdaq:AMRS), a leading renewable chemicals and fuels company, today announced financial results for the third quarter ended September 30, 2012.

"During the third quarter, we realized the benefits of our focused strategy with lower operating costs and increased sales of our renewable products. Our technology improvements continue and our commercialization activities remain on track," said John Melo, President & CEO of Amyris.

"Amyris's industrial-scale farnesene production facility at Paraíso is in the final stages of a successful commissioning and we remain confident about commercial production in early 2013," Melo concluded.


Aggregate revenues for the quarter ended September 30, 2012 were $19.1 million versus $36.3 million in the third quarter of 2011. The decline in revenue was due to the Company's planned transition out of the ethanol and ethanol-blended gasoline business, which is now complete. Partially offsetting this decline were increased revenues from renewable products sales and collaborations, primarily related to the amendment of the Company's collaboration agreement with Total.

Total research & development and sales, general & administrative expenses declined 26% to $33.1 million for the quarter from the same quarter the prior year primarily due to lower compensation and benefits expense.

GAAP net loss attributable to common stockholders for the quarter was $20.3 million ($0.34 per share) compared to a loss of $43.7 million ($0.97per share) in the same quarter of 2011. On a non-GAAP basis, excluding non-cash items such as stock-based compensation, the net loss attributable to common stockholders was $12.9 million ($0.22 per share) compared to $36.8 million ($0.82 per share) in the prior year. A reconciliation of GAAP to non-GAAP results is included in this release.

The Company's balance of cash, cash equivalents and short-term investments at the end of the third quarter was $44.4 million.


Amyris will discuss these results and provide a business update, including funding requirements, in a conference call scheduled for today at 5:00 pm ET (2:00 pm PT). Investors may access a live audio webcast of this conference call and the earnings call presentation in the investor relations section of the Company's website at A replay of the webcast will be available on the investor relations section of the Company's website approximately two hours after the conclusion of the call and remain available for approximately 60 calendar days.

About Amyris

Amyris is an integrated renewable products company focused on providing sustainable alternatives to a broad range of petroleum-sourced products. Amyris uses its industrial synthetic biology platform to convert plant sugars into a variety of molecules -- flexible building blocks that can be used in a wide range of products. Amyris's initial portfolio of commercial products is based on Biofene®, Amyris's brand of renewable farnesene, a long-chain hydrocarbon. Amyris is commercializing these products both as No Compromise® renewable ingredients in cosmetics, flavors and fragrances, polymers, lubricants and consumer products, and also as No Compromise renewable diesel and jet fuel. Amyris Brasil Ltda., a subsidiary of Amyris, oversees the establishment and expansion of Amyris's production in Brazil. More information about Amyris is available at

The Amyris, Inc. logo is available at

Forward-Looking Statements 

This release contains forward-looking statements, and any statements other than statements of historical facts could be deemed to be forward-looking statements. These forward-looking statements include, among other things, statements regarding future events (such as commercialization activities, commissioning of a planned production facility, and commercial production commencement) that involve risks and uncertainties. These statements are based on management's current expectations and actual results and future events may differ materially due to risks and uncertainties, including those associated with any delays or failures in development, production and commercialization of products, liquidity and ability to fund capital expenditures, Amyris's reliance on third parties to achieve its goals, and other risks detailed in the "Risk Factors" section of Amyris's quarterly report on Form 10-Q filed on August 8, 2012Amyris disclaims any obligation to update information contained in these forward-looking statements whether as a result of new information, future events, or otherwise.

Non-GAAP Financial Information

Consolidated financial information has been presented in accordance with GAAP as well as on a non-GAAP basis. The non-GAAP financial measures exclude non-cash items such as stock-based compensation. Management believes that it is useful to supplement its GAAP financial statements with this non-GAAP information because management uses such information internally for its operating, budgeting and financial planning purposes. These non-GAAP financial measures also facilitate management's internal comparisons to Amyris's historical performance as well as comparisons to the operating results of other companies. In addition, Amyris believes these non-GAAP financial measures are useful to investors because they allow for greater transparency into the indicators used by management as a basis for its financial and operational decision making. Non-GAAP information is not prepared under a comprehensive set of accounting rules and therefore, should only be read in conjunction with financial information reported under U.S. GAAP when understanding Amyris's operating performance. Reconciliation between GAAP and non-GAAP financial information is provided in the financial statement tables below.

Amyris, the Amyris logo, Biofene and No Compromise are trademarks or registered trademarks of Amyris, Inc.

Amyris, Inc. 
Condensed Consolidated Statement of Operations
(In thousands, except per share data)
  Three Months Ended
September 30,
Nine Months Ended
September 30,
  2012 2011 2012 2011
Product sales  $ 4,728  $ 31,162  $ 46,615  $ 92,998
Grants and collaborations revenue  14,380  5,114  21,225  12,454
Total revenues  19,108  36,276  67,840  105,452
Costs and operating expenses        
Cost of products sold  4,444  35,729  71,891  99,247
Loss on purchase commitments and write off of production assets  1,438  --   38,090  -- 
Research and development (1)  15,736  23,441  55,580  66,622
Sales, general and administrative (1)  17,355  21,174  61,301  59,401
Total costs and operating expenses  38,973  80,344  226,862  225,270
Loss from operations  (19,865)  (44,068)  (159,022)  (119,818)
Other income (expense):        
Interest income  297  609  1,406  1,250
Interest expense  (1,224)  (291)  (3,538)  (1,172)
Other income (expense), net  664  310  (512)  160
Total other income (expense)  (263)  628  (2,644)  238
Loss before income taxes  (20,128)  (43,440)  (161,666)  (119,580)
Provision for income taxes  (260)  (474)  (753)  (299)
Net loss  $ (20,388)  $ (43,914)  $ (162,419)  $(119,879)
Net loss attributable to noncontrolling interest  95  224  772  437
Net loss attributable to Amyris, Inc. common stockholders  $ (20,293)  $ (43,690)  $ (161,647)  $(119,442)
Net loss per share attributable to common stockholders, basic and diluted  $ (0.34)  $ (0.97)  $ (2.91)  $ (2.68)
Weighted-average shares of common stock outstanding used in computing net loss per share of common stock, basic and diluted 58,964,226 45,031,613 55,552,949 44,507,686
(1) Includes stock-based compensation expense of the following for the periods presented:        
Research and development  $ 1,450  $ 1,711  $ 4,521  $ 4,697
Sales, general and administrative  4,515  5,162  16,879  14,139
   $ 5,965  $ 6,873  $ 21,400  $ 18,836
Amyris, Inc. 
Condensed Consolidated Balance Sheets
(In thousands)
  September 30, December 31,
  2012 2011
Current assets:    
Cash, cash equivalents and short-term investments  $ 44,429  $ 103,592
Accounts receivable, net 3,807 6,936
Inventories, net 8,311 9,070
Prepaid expenses and other current assets 9,995 19,873
Total current assets 66,542 139,471
Property and equipment, net 164,703 128,101
Restricted cash  954  -- 
Other assets 20,133 43,001
Goodwill and intangible assets 9,248 9,538
Total assets  $ 261,580   $ 320,111 
Liabilities and Equity    
Current liabilities:    
Accounts payable  $ 18,374  $ 26,379
Deferred revenue  1,532  3,139
Accrued and other current liabilities  24,061  30,982
Capital lease obligation, current portion  1,871  3,717
Debt, current portion  2,121  28,049
Total current liabilities  47,959  92,266
Capital lease obligation, net of current portion  1,495  2,619
Long-term debt, net of current portion  103,289  13,275
Deferred rent, net of current portion  8,886  9,957
Deferred revenue, net of current portion  4,396  4,097
Other liabilities  18,893  37,085
Total liabilities  184,918  159,299
Amyris, Inc. stockholders' equity   77,465  161,052
Noncontrolling interest  (803)  (240)
Total stockholders' equity   76,662  160,812
Total liabilities and stockholders' equity  $ 261,580   $ 320,111 
Amyris, Inc. 
Supplemental Consolidated Financial Information 
(In thousands, except per share data)
  Three Months Ended September 30, Nine Months Ended September 30,
  2012 2011 2012 2011
Other Selected Financial Information:        
Capital expenditures and deposits on property and equipment  $ 5,541  $ 40,769  $ 50,906  $ 71,248
Depreciation and amortization  $ 3,179  $ 2,897  $ 10,686  $ 7,728
Product sales        
Ethanol and Ethanol-blended Gasoline  $ 1,657  $ 31,096  $ 38,836  $ 92,900
Renewables  3,071  66  7,779  98
Total product sales  $ 4,728   $ 31,162   $ 46,615   $ 92,998 
Reconciliation of GAAP to Non-GAAP Net Loss Per Share:      
Net loss attributable to Amyris Inc., common stockholders (GAAP)  $ (20,293)  $ (43,690)  $ (161,647)  $ (119,442)
Stock-based compensation expense  5,965  6,873  21,400  18,836
Loss on purchase commitments and write off of production assets  1,438  --   38,090  -- 
Net loss attributable to Amyris Inc., common stockholders (Non- GAAP)  $ (12,890)  $ (36,817)  $ (102,157)  $ (100,606)
Net loss per share attributed to common stockholders         
basic and diluted (GAAP)  $ (0.34)  $ (0.97)  $ (2.91)  $ (2.68)
Stock-based compensation expense  0.10  0.15  0.39  0.42
Loss on purchase commitments and write off of production assets  0.02  --   0.68  -- 
Net loss per share attributed to common stockholders, basic and diluted (Non-GAAP)  $ (0.22)  $ (0.82)  $ (1.84)  $ (2.26)

company logo

Source:  Amyris, Inc.


News Provided by Acquire Media

Contact Us

Beth Bannerman
Chief Engagement & Sustainability Officer
Amyris, Inc.